2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. 2006

Jang-Yang Chang, and Ming-Fang Yang, and Chi-Yen Chang, and Chi-Ming Chen, and Ching-Chuan Kuo, and Jing-Ping Liou
Institute of Cancer Research, National Health Research Institutes, Taipei 114, Taiwan.

A novel series of 2-amino and 2'-aminocombretastatin derivatives were synthesized and evaluated for antitumor activity. Several compounds had excellent antiproliferative activity as inhibitors of tubulin polymerization. Compounds 11, 20, and 21 with IC(50) values of 1.6, 1.7, and 1.8 microM, respectively, exhibited more potent inhibition of tubulin polymerization than colchicine and approximately as active as combretastatin A-4. They also displayed antiproliferative activity with an IC(50) values ranging from 11 to 44 nM in a variety of human cell lines from different organs. Structure activity relationship information suggests that the NH(2) substituent at the 2-position of either ring A or ring B in combretastatin molecular skeleton may play an important role in the bioactivity of this series of compounds.

UI MeSH Term Description Entries
D003078 Colchicine A major alkaloid from Colchicum autumnale L. and found also in other Colchicum species. Its primary therapeutic use is in the treatment of gout, but it has been used also in the therapy of familial Mediterranean fever (PERIODIC DISEASE). Colchicine, (+-)-Isomer,Colchicine, (R)-Isomer
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013267 Stilbenes Organic compounds that contain 1,2-diphenylethylene as a functional group. Stilbene,Stilbene Derivative,Stilbene Derivatives,Stilbenoid,Stilbenoids,Derivative, Stilbene,Derivatives, Stilbene
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D050257 Tubulin Modulators Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES. Microtubule Modulator,Tubulin Inhibitor,Tubulin Modulator,Tubulin Polymerization Inhibitor,Tubulin Polymerization Promoter,Tubulin Promoter,Microtubule Modulators,Tubulin Inhibitors,Tubulin Polymerization Inhibitors,Tubulin Polymerization Promoters,Tubulin Promoters,Inhibitor, Tubulin,Inhibitor, Tubulin Polymerization,Inhibitors, Tubulin,Inhibitors, Tubulin Polymerization,Modulator, Microtubule,Modulator, Tubulin,Modulators, Microtubule,Modulators, Tubulin,Polymerization Inhibitor, Tubulin,Polymerization Inhibitors, Tubulin,Polymerization Promoter, Tubulin,Polymerization Promoters, Tubulin,Promoter, Tubulin,Promoter, Tubulin Polymerization,Promoters, Tubulin,Promoters, Tubulin Polymerization
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug

Related Publications

Jang-Yang Chang, and Ming-Fang Yang, and Chi-Yen Chang, and Chi-Ming Chen, and Ching-Chuan Kuo, and Jing-Ping Liou
December 2004, Bioorganic & medicinal chemistry letters,
Jang-Yang Chang, and Ming-Fang Yang, and Chi-Yen Chang, and Chi-Ming Chen, and Ching-Chuan Kuo, and Jing-Ping Liou
February 2009, Bioorganic & medicinal chemistry,
Jang-Yang Chang, and Ming-Fang Yang, and Chi-Yen Chang, and Chi-Ming Chen, and Ching-Chuan Kuo, and Jing-Ping Liou
July 2001, Bioorganic & medicinal chemistry letters,
Jang-Yang Chang, and Ming-Fang Yang, and Chi-Yen Chang, and Chi-Ming Chen, and Ching-Chuan Kuo, and Jing-Ping Liou
December 2001, Journal of medicinal chemistry,
Jang-Yang Chang, and Ming-Fang Yang, and Chi-Yen Chang, and Chi-Ming Chen, and Ching-Chuan Kuo, and Jing-Ping Liou
November 2013, Journal of medicinal chemistry,
Jang-Yang Chang, and Ming-Fang Yang, and Chi-Yen Chang, and Chi-Ming Chen, and Ching-Chuan Kuo, and Jing-Ping Liou
November 2001, Journal of medicinal chemistry,
Jang-Yang Chang, and Ming-Fang Yang, and Chi-Yen Chang, and Chi-Ming Chen, and Ching-Chuan Kuo, and Jing-Ping Liou
January 2018, Current medicinal chemistry,
Jang-Yang Chang, and Ming-Fang Yang, and Chi-Yen Chang, and Chi-Ming Chen, and Ching-Chuan Kuo, and Jing-Ping Liou
July 2015, Bioorganic & medicinal chemistry,
Jang-Yang Chang, and Ming-Fang Yang, and Chi-Yen Chang, and Chi-Ming Chen, and Ching-Chuan Kuo, and Jing-Ping Liou
March 2009, Bioorganic & medicinal chemistry letters,
Jang-Yang Chang, and Ming-Fang Yang, and Chi-Yen Chang, and Chi-Ming Chen, and Ching-Chuan Kuo, and Jing-Ping Liou
May 2011, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!